Rapid Micro Biosystems (RPID) H.C. Wainwright 27th Annual Global Investment Conference summary

Business Overview and Market Opportunity

• Focused on modernizing microbial quality control in pharmaceutical manufacturing with automated technology and data integrity.

• Serves a $10 billion+ global market, with half in hardware and half in recurring consumables, driven by regulatory scrutiny and demand for complex therapies.

• 75% of the top 20 global pharma companies and 86% of approved CAR-T manufacturers use the system.

• Installed over 170 systems globally, validated in more than 20 countries, with a strong presence in top biopharma and CAR-T companies.

• Expansion opportunities exist in biologics, cell and gene therapies, personal care, medical devices, cosmetics, food & beverage, and adjacent markets.

Financial Performance and Growth Strategy

• Achieved $28 million in revenue in 2024, growing at 25% year-over-year, with a multi-year CAGR target of 25–30% through 2027.

• Over 50% of revenue is recurring, with $15 million in recurring revenue and each system generating $150,000–$200,000 annually.

• More than 170 cumulative system placements and 150 validations across 20 countries as of June 2025.

• Growth strategy includes land-and-expand with current customers, new product launches, geographic expansion (especially in Asia), and thousands of untapped sites.

• Gross margin expansion to 50% by 2027 supported by reduced product costs, manufacturing efficiency, and volume increases.

Technology and Value Proposition

• Growth Direct platform automates water, bioburden, environmental, and sterility testing, integrating with lab management systems.

• Delivers faster, more reliable results, improving data integrity and operational efficiency, with 50% faster results and regulatory compliance.

• Reduces manual labor, minimizes errors, and accelerates product release by providing results in 1–1.5 days versus 7 days.

• Only fully automated solution in the market, providing a first-mover advantage, strong barriers to entry, and a robust patent portfolio.

• Emphasis on automation, data services, AI, and SaaS to drive future growth.